Equity Analysis /
United States of America

US : Lannett Company, Inc. - LCI | Initiates Pivotal Study for Insulin Glargine Biosimilar Targeting Potential $300M Opportunity

    Michael Parolari
    Michael Parolari

    Research Associate

    CGS-CIMB
    29 March 2022
    Published by